Other News To Note
Friday, March 25, 2011
AltheRx Inc., of Chadds Ford, Pa., purchased from GlaxoSmithKline plc, of London, Solabegron, a beta3-adrenoceptor agonist that has demonstrated positive results in Phase II programs for the treatment of overactive bladder in women and irritable bowel syndrome. The company said it plans to advance the overactive bladder program for Solabegron into Phase III this year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.